ASCENDO BIOTECHNOLOGY, INC. TAIWAN BRANCH (CAYMAN ISLANDS)
Update:2026/01/07
Industries
Main Industry
Biotechnology
Main Product/Service
Their lead asset, ASD141, is a first‑in‑class monoclonal antibody that blocks the innate immune checkpoint TLT‑1 to reshape the tumor microenvironment and enhance anti‑tumor immunity.
They are also developing ASD001, an antibody aimed at rebalancing over
They are also developing ASD001, an antibody aimed at rebalancing over
Founded Year
2019
Unified Business No.
85070076
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Ascendo Biotechnology, founded in 2019, is a clinical‑stage biotech company developing novel immunotherapies by targeting innate immune pathways to treat cancer and autoimmune diseases.